Copertina

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely

Junko H Ohyashiki,1 Kazushige Ohtsuki,1 Izuru Mizoguchi,2 Takayuki Yoshimoto,2 Seiichiro Katagiri,3 Tomohiro Umezu,1,4 Kazuma Ohyashiki3,4 1Department of Molecular Oncology, Institute of Medical Science, 2Department of Immunoregulation, Institute of Medical Science, 3Department of Hematolog...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autori principali:	Ohyashiki JH (Autore), Ohtsuki K (Autore), Mizoguchi I (Autore), Yoshimoto T (Autore), Katagiri S (Autore), Umezu T (Autore), Ohyashiki K (Autore)
Natura:	Libro
Pubblicazione:	Dove Medical Press, 2014-08-01T00:00:00Z.
Soggetti:	article
Accesso online:	Connect to this object online.
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
di: Alexandra Rodrigues Alves, et al.

A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome
di: Asano M, et al.
Pubblicazione: (2019)

Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells
di: Satoshi Imanishi, et al.
Pubblicazione: (2018)

The C allele of <it>JAK2 </it>rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
di: Ohyashiki Junko H, et al.
Pubblicazione: (2012)

The Undetected
di: Smith, George O. (George Oliver), 1911-1981; Finlay, Virgil, 1914-1971 [Illustrator]

Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia
di: Pradeep Balasubramanian, et al.
Pubblicazione: (2015)

Imatinib associated discoid lupus erythematosus in a patient with chronic myeloid leukemia
di: Priya Sarlashkar, BS, et al.
Pubblicazione: (2024)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
di: Ronan Swords, et al.
Pubblicazione: (2009)

Hypoxia-induced paclitaxel resistance in cervical cancer modulated by miR-100 targeting of USP15
di: Hirotaka Nishi, et al.
Pubblicazione: (2023)

Estimating undetected Ebola spillovers.
di: Emma E Glennon, et al.
Pubblicazione: (2019)

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
di: Gian Paolo Bombeccari, et al.
Pubblicazione: (2017)

Multiple eruptive dermatofibromas secondary to imatinib mesylate in a patient with chronic myeloid leukemia
di: Francisco J Lira-Valero, et al.
Pubblicazione: (2021)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
di: Martin Henkes, et al.
Pubblicazione: (2008)

Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients
di: Heriberto Bruzzoni-Giovanelli, et al.
Pubblicazione: (2024)

Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
di: Aypara Hasanova, et al.
Pubblicazione: (2023)

Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?
di: Jessica Parrott, et al.
Pubblicazione: (2017)

Quantification of undetectable plasma HIV RNA
di: N. Margot, et al.
Pubblicazione: (2017)

Undetected hypothyroidism and unexpected anesthetic complications
di: P Sudha, et al.
Pubblicazione: (2012)

Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report
di: Meenakshi Sachdeva, et al.
Pubblicazione: (2023)

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
di: Hyacinthe Johnson-Ansah, et al.
Pubblicazione: (2022)

Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience
di: Josephine A. Adattini, et al.
Pubblicazione: (2022)

Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
di: Parveen Jain, et al.
Pubblicazione: (2013)

Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia
di: Qing Wang, et al.
Pubblicazione: (2020)

Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events
di: Pavel Burda, et al.
Pubblicazione: (2024)

Panoramic radiographs for identifying individuals with undetected osteoporosis
di: Akira Taguchi
Pubblicazione: (2009)

Disseminated neuroendocrine neoplasm with undetected primary tumor
di: Frederico Becker Ribeiro, et al.
Pubblicazione: (2012)

Imatinib induced lichen planus
di: R Sudha, et al.
Pubblicazione: (2011)

Overexpression of MicroRNA-148b-3p stimulates osteogenesis of human bone marrow-derived mesenchymal stem cells: the role of MicroRNA-148b-3p in osteogenesis
di: Samaneh Mollazadeh, et al.
Pubblicazione: (2019)

Bartonella henselae endocarditis in Laos - 'the unsought will go undetected'.
di: Sayaphet Rattanavong, et al.
Pubblicazione: (2014)

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia
di: Yan Chen, et al.
Pubblicazione: (2020)

Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia
di: Josephine A. Adattini, et al.
Pubblicazione: (2023)

The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
di: Muhammad Darwin Prenggono, et al.
Pubblicazione: (2021)

Study of correlation between imatinib mesylate plasma levels and hematological profile of patients undergoing treatment for chronic myeloid leukemia
di: Emanuelle S. Dal Ponte, et al.
Pubblicazione: (2017)

Status and analysis of undetected plague cases in Yunnan Province, China
di: Chao Su, et al.
Pubblicazione: (2024)

HIV knowledge and its correlation with the Undetectable = Untransmittable slogan in Brazil
di: Rayane C. Ferreira, et al.
Pubblicazione: (2022)

Polymorphisms in Drug Transporter and Metabolism Genes Associated with Resistance to Imatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
di: Ana Marcela Arrieta Gómez, et al.
Pubblicazione: (2023)

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
di: Caroline Regina de Jesus, et al.
Pubblicazione: (2011)

"Journey of Uncertainties:" Nature of Transitioning among Persons Living with Undetectable HIV
di: Rudolf Cymorr Kirby Martinez
Pubblicazione: (2020)

Modeling undetected poliovirus circulation following the 2022 outbreak in the United States
di: Dominika A. Kalkowska, et al.
Pubblicazione: (2024)

From Undetectable Equals Untransmittable (U=U) to Breastfeeding: Is the Jump Short?
di: Tullio Prestileo, et al.
Pubblicazione: (2022)